Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Investigations into prognostic factors in progressive supranuclear palsy have shown conflicting results. We performed a retrospective study in order to identify clinical predictors of survival in clinically diagnosed progressive supranuclear palsy patients referred to our centre. Methods Data on medical history, survival and five clinical disability milestones (inability to walk unassisted, unintelligible speech, severe dysphagia, dementia and institutionalization) were collected from outpatients' medical records and by a telephone interview to caregivers. Patients were subdivided into Richardson's syndrome and PSP-Parkinsonism according to symptoms during the first 2 years of disease. Survival was analyzed by the Kaplan-Meier method and Cox regression analysis. Results Forty-three consecutive patients were enrolled (86% Richardson's syndrome). Motor disturbances were the most frequent symptoms of onset. During the follow-up, 60.5% of patients died after a median survival of 7.1 years (2.2-18). Older age at onset (>63) (HR 2.8; 95% CI: 1.3-5.7; p = 0.007), early dysphagia (HR 2.3; 95% CI: 1-5.3; p = 0.05) and early cognitive deficits (HR 3.6; 95% CI: 1.6-8.2; p = 0.002) were predictors of shorter survival. Compared to PSP-Parkinsonism patients, Richardson's syndrome patients had shorter survival and higher mortality risk although not statistically significant (HR 3 95% CI: 0.9-9.9; p = 0.07). Seventy-seven percent of patients developed severe disability during follow-up: shorter time to the first clinical disability milestone predicted shorter survival (HR 7.8; 95% CI: 2.3-26; p = 0.0008). Conclusions early dysphagia, cognitive impairment, older age at onset, and time to disability were predictors of shorter survival; Richardson's syndrome had a less favorable course than PSP-Parkinsonism. Clinical milestones should be considered as possible endpoints in future clinical trials.

What this study adds

Evidence grade: Low

This retrospective study of 43 patients with clinically diagnosed progressive supranuclear palsy found that older age at onset, early dysphagia and early cognitive deficits predicted shorter survival. Reported effect size: 60.5%; HR 2.8; HR 2.3.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

dell'Aquila, C., Zoccolella, S., Cardinali, V., de Mari, M., Iliceto, G., Tartaglione, B., et al. (2013). Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism & related disorders. https://doi.org/10.1016/j.parkreldis.2013.06.014

Vancouver

dell'Aquila C, Zoccolella S, Cardinali V, de Mari M, Iliceto G, Tartaglione B, et al. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism & related disorders. 2013. doi:10.1016/j.parkreldis.2013.06.014. PMID: 23968651.

BibTeX

@article{dellaquila2013-23968651,
  author  = {dell'Aquila, C. and Zoccolella, S. and Cardinali, V. and de Mari, M. and Iliceto, G. and Tartaglione, B. and Lamberti, P. and Logroscino, G.},
  title   = {{Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients}},
  journal = {Parkinsonism \& related disorders},
  year    = {2013},
  doi     = {10.1016/j.parkreldis.2013.06.014},
  pmid    = {23968651},
  url     = {https://doi.org/10.1016/j.parkreldis.2013.06.014}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This retrospective study of 43 patients with clinically diagnosed progressive supranuclear palsy found that older age at onset, early dysphagia and early cognitive deficits predicted shorter survival. It is about prognosis in this disease and does not test any treatment, cure or prevention.

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 43 of 100.43 of 100 points earned57 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Parkinsonism & related disorders)
Journal's citation record 2 / 4 Parkinsonism & Related Disorders: journal h-index 155 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 115 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.7 citations a year over 15 year(s) since 2013
Impact for its field and year 3 / 6 Cited 3.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Giancarlo Logroscino: h-index 126 (OpenAlex, whole career)
Institution's track record 0 / 3 University of Bari Aldo Moro: institution h-index 586 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23968651)
Free to read 0 / 2 Behind a paywall — scores zero
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Digital health tools from nearby years

Also in Digital health tools

178 studies in the library are filed under Digital health tools with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Digital health tools hub.

Similar studies

More on Digital health tools

See all studies in Digital health tools →